[fcb5af]: / literature / by_gene / KMT2D.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 33579790 10.1136/gutjnl-2020-322935 2022 Oncogenetic landscape of lymphomagenesis in coeliac disease. KMT2D
2 34265801 10.1097/PAS.0000000000001780 2022 Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation. KMT2D
3 34325497 10.4143/crt.2021.752 2022 Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. KMT2D
4 34494161 10.1007/s00428-021-03186-3 2022 Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin. KMT2D
5 34515044 10.1159/000518227 2022 A Patient with Kabuki Syndrome Mutation Presenting with Very Severe Aplastic Anemia. KMT2D
6 34553842 10.1002/cnr2.1559 2022 Genetic features of B-cell lymphoblastic lymphoma with TCF3-PBX1. KMT2D
7 34601504 10.1038/s41379-021-00938-z 2022 Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation. KMT2D
8 34654055 10.1182/bloodadvances.2021006034 2022 Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. KMT2D
9 34664256 10.1111/bjh.17894 2022 Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. KMT2D
10 34837284 10.1111/cas.15224 2022 Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma. KMT2D
11 34957565 10.1002/path.5861 2022 Widespread in situ follicular neoplasia in patients who subsequently developed follicular lymphoma. KMT2D
12 34967008 10.1111/bjh.17990 2022 The molecular ontogeny of follicular lymphoma: gene mutations succeeding the BCL2 translocation define common precursor cells. KMT2D
13 34977845 10.1016/j.xjidi.2021.100068 2022 Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders. KMT2D
14 34980601 10.1158/1078-0432.CCR-21-2949 2022 Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. KMT2D
15 35022084 10.1186/s13046-021-02234-9 2022 The follicular lymphoma epigenome regulates its microenvironment. KMT2D
16 35038193 10.1111/his.14617 2022 Incidence, clinicopathological features and genetics of in-situ follicular neoplasia: a comprehensive screening study in a Japanese cohort. KMT2D
17 35045798 10.1080/10428194.2021.2024821 2022 High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma. KMT2D
18 35058282 10.1101/mcs.a006156 2022 Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report. KMT2D
19 35240014 10.4143/crt.2022.017 2022 Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. KMT2D
20 35266562 10.1002/ajh.26523 2022 Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. KMT2D
21 35300216 10.2147/JIR.S341355 2022 The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma. KMT2D
22 35317330 10.14740/wjon1436 2022 Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis. KMT2D
23 35363872 10.1182/bloodadvances.2021005284 2022 Molecular subclusters of follicular lymphoma: a report from the UK's Haematological Malignancy Research Network. KMT2D
24 35411950 10.1002/cbf.3702 2022 USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma. KMT2D
25 35522148 10.3324/haematol.2021.280005 2022 Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase <i>KDM4C</i> in B cell lymphomas. KMT2D
26 35646048 10.3389/fgene.2022.878618 2022 Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. KMT2D
27 35816682 10.1182/bloodadvances.2022008355 2022 Genomic and microenvironmental landscape of stage I follicular lymphoma, compared to stage III/IV. KMT2D
28 35879731 10.1186/s40364-022-00401-4 2022 Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma. KMT2D
29 35882439 10.1182/bloodadvances.2022007541 2022 Genetic and immunohistochemical profiling of NK/T-cell Lymphomas reveals prognostically relevant BCOR-MYC association. KMT2D
30 35908982 10.1016/j.blre.2022.100992 2022 Follicular lymphoma: The long and winding road leading to your cure? KMT2D
31 35937947 10.1155/2022/6441139 2022 Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis. KMT2D
32 36048893 10.1093/ajcp/aqac104 2022 Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant. KMT2D
33 36055572 10.1016/j.clim.2022.109105 2022 A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma. KMT2D
34 36081566 10.3389/fonc.2022.941347 2022 Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx. KMT2D
35 32855278 10.3324/haematol.2020.254854 2021 Genetic evolution of <i>in situ</i> follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype. KMT2D
36 32929178 10.1038/s41379-020-00673-x 2021 The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. KMT2D
37 32973328 10.1038/s41379-020-00685-7 2021 The clinicopathological and molecular features of sinusoidal large B-cell lymphoma. KMT2D
38 33152759 10.1182/blood.2020005381 2021 Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. KMT2D
39 33413063 10.2174/1568009620666210106122750 2021 Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). KMT2D
40 33431788 10.1038/s41392-020-00437-8 2021 CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. KMT2D
41 33432228 10.1038/s41590-020-00827-8 2021 Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. KMT2D
42 33436855 10.1038/s41598-020-80613-6 2021 Targeted sequencing to identify genetic alterations and prognostic markers in pediatric T-cell acute lymphoblastic leukemia. KMT2D
43 33479306 10.1038/s41598-020-80376-0 2021 Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma. KMT2D
44 33544565 10.1097/PAS.0000000000001658 2021 Immunophenotypic Spectrum and Genomic Landscape of Refractory Celiac Disease Type II. KMT2D
45 33560380 10.1182/bloodadvances.2020002469 2021 Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. KMT2D
46 33562694 10.3390/cancers13040641 2021 Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention. KMT2D
47 33569430 10.21037/atm-20-7574 2021 Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity. KMT2D
48 33581493 10.1016/j.ctarc.2021.100310 2021 Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients. KMT2D
49 33655698 10.1002/cam4.3649 2021 Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. KMT2D
50 33747936 10.3389/fonc.2021.622648 2021 Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. KMT2D
51 33786580 10.1182/blood.2020008743 2021 KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. KMT2D
52 33809641 10.3390/cancers13061340 2021 Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms. KMT2D
53 33829512 10.1111/his.14378 2021 Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma. KMT2D
54 33881803 10.1111/ijlh.13534 2021 A lineage switch from NPM1-mutant acute myeloid leukemia to acute T-cell lymphoblastic leukemia with KMT2D and ARID2 mutant. KMT2D
55 33939500 10.1177/10668969211013402 2021 A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor. KMT2D
56 33945543 10.1371/journal.pone.0248886 2021 Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes. KMT2D
57 33964277 10.1016/j.humpath.2021.04.014 2021 Relative frequency and clinicopathologic characteristics of MYC-rearranged follicular lymphoma. KMT2D
58 34039950 10.1038/s41408-021-00493-5 2021 Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing. KMT2D
59 34080947 10.1080/10428194.2021.1933480 2021 Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets. KMT2D
60 34256839 10.1186/s40164-021-00232-3 2021 Progress in molecular feature of smoldering mantle cell lymphoma. KMT2D
61 34334687 10.1097/PAS.0000000000001726 2021 High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B. KMT2D
62 34350060 10.1080/2162402X.2021.1928365 2021 Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. KMT2D
63 34535012 10.1182/bloodadvances.2021004562 2021 Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. KMT2D
64 34558064 10.1111/bjh.17824 2021 Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases. KMT2D
65 34570179 10.1182/bloodadvances.2021004668 2021 Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. KMT2D
66 34590470 10.52586/4970 2021 Methylation alterations and advance of treatment in lymphoma. KMT2D
67 34621263 10.3389/fimmu.2021.688493 2021 Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. KMT2D
68 34671837 10.1007/s00292-021-01011-x 2021 [Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma]. KMT2D
69 34745101 10.3389/fimmu.2021.732006 2021 International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma. KMT2D
70 34925435 10.3389/fgene.2021.677650 2021 Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing. KMT2D
71 35008340 10.3390/cancers14010176 2021 Recent Advances in the Genetic of MALT Lymphomas. KMT2D
72 35071240 10.3389/fcell.2021.805195 2021 Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. KMT2D
73 35846093 10.1002/jha2.131 2021 Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma. KMT2D
74 31028364 10.1038/s41379-019-0279-8 2020 Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. KMT2D
75 31537689 10.3324/haematol.2018.214056 2020 <i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. KMT2D
76 31705772 10.1002/gcc.22825 2020 Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement. KMT2D
77 31738823 10.1182/blood.2019002699 2020 Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. KMT2D
78 31752573 10.1080/10428194.2019.1691200 2020 New murine models of aggressive lymphoma. KMT2D
79 31774495 10.1182/blood.2019001904 2020 Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. KMT2D
80 31776129 10.1101/mcs.a004614 2020 Dramatic increase in gene mutational burden after transformation of follicular lymphoma into TdT<sup>+</sup> B-lymphoblastic leukemia/lymphoma. KMT2D
81 31807922 10.1007/s00428-019-02691-w 2020 Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature. KMT2D
82 31886867 10.1093/jnen/nlz125 2020 Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma. KMT2D
83 31980558 10.1136/jclinpath-2019-206282 2020 Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. KMT2D
84 32010998 10.1002/hon.2720 2020 Refractory celiac disease type II: An atypical case highlighting limitations of the current classification system. KMT2D
85 32012328 10.1002/hon.2718 2020 High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. KMT2D
86 32064880 10.4149/neo_2020_190307N194 2020 KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients. KMT2D
87 32127923 10.1177/1758835919900856 2020 Epigenetic aberrations in natural killer/T-cell lymphoma: diagnostic, prognostic and therapeutic implications. KMT2D
88 32164600 10.1186/s12885-020-6709-7 2020 Genetic mutational analysis of pediatric acute lymphoblastic leukemia from a single center in China using exon sequencing. KMT2D
89 32239385 10.1007/s11523-020-00710-4 2020 Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib. KMT2D
90 32239765 10.1002/ajh.25796 2020 Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. KMT2D
91 32349779 10.1186/s13073-020-00739-0 2020 CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial. KMT2D
92 32350066 10.1158/0008-5472.CAN-19-2247 2020 FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells. KMT2D
93 32399964 10.1002/ijc.33049 2020 Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup. KMT2D
94 32459397 10.1111/jcmm.15425 2020 Establishment and characterization of a novel 'double-hit' follicular lymphoma cell line, FL-SJC. KMT2D
95 32469082 10.1002/cncr.32866 2020 Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma. KMT2D
96 32589730 10.1182/bloodadvances.2020001696 2020 Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. KMT2D
97 32682634 10.1016/j.jdermsci.2020.06.013 2020 Hydroa vacciniforme-like lymphoproliferative disorder: A study of clinicopathology and whole-exome sequencing in Chinese patients. KMT2D
98 32695399 10.1186/s40364-020-00205-4 2020 Plasma circulating tumor DNA assessment reveals <i>KMT2D</i> as a potential poor prognostic factor in extranodal NK/T-cell lymphoma. KMT2D
99 32770099 10.1038/s41598-020-70310-9 2020 Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study. KMT2D
100 32871937 10.1097/MD.0000000000021938 2020 Aggressive variant of splenic marginal zone lymphoma characterized using a cancer panel test and treated with rituximab-containing chemotherapy: A case report. KMT2D